{"entity":{"id":"nct06818643","kind":"trial","name":"A Study to Evaluate the Safety and Efficacy of MK-3120 in Participants With Advanced Solid Tumors (MK-3120-002)","aka":[],"tldr":"A phase 1/2 trial of MK-3120 in advanced solid tumours, run by Merck Sharp & Dohme LLC, now recruiting.","summary":"A Study to Evaluate the Safety and Efficacy of MK-3120 in Participants With Advanced Solid Tumors (MK-3120-002) is a phase 1/2 interventional study registered as NCT06818643 by Merck Sharp & Dohme LLC, with 270 participants planned, started 2025-03-25 and due to reach its primary completion in 2028-10-25. Interventions recorded: MK-3120.","status":"recruiting","asOf":"2026-09-16","links":[{"label":"ClinicalTrials.gov NCT06818643","url":"https://clinicaltrials.gov/study/NCT06818643"}],"tags":["pipeline","ctgov-ingest"],"related":[],"cancers":["metastatic-cancer"],"sections":[],"technologies":[],"targets":[],"drugs":[],"companies":["merck"],"institutions":[],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"notes":[],"nct":"NCT06818643","phase":"1/2","setting":"A Phase 1/2 Open-label Study to Evaluate the Safety and Efficacy of MK-3120 in Participants With Advanced Solid Tumors","sponsor":"Merck Sharp & Dohme LLC","enrolled":270,"outcomes":[]},"route":"/trials/nct06818643/","neighbours":{"cancer":[{"id":"metastatic-cancer","kind":"cancer","name":"Metastatic cancer (cancer that has spread)","route":"/cancers/metastatic-cancer/"}],"company":[{"id":"merck","kind":"company","name":"Merck & Co. (MSD)","route":"/companies/merck/"}]}}